RG6221
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 13, 2025
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=34 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting | N=180 ➔ 34
Enrollment change • Enrollment closed • Oncology • Solid Tumor
March 26, 2025
FAP-LTBR (RO7567132): A first-in-class bi-specific stromal immunomodulatory agonist designed to enable and enhance efficacy of cancer immunotherapies
(AACR 2025)
- P1 | "Treatment with the murine surrogate of RO7567132 led to tumor growth inhibition in a breast cancer model and showed greater efficacy when combined with the murine surrogate of atezolizumab in both breast cancer and fibrosarcoma models. Additionally, in a slow-growing orthotopic mouse colorectal cancer model, treatment with the murine surrogate of RO7567132 increased the content of immune cells (T and B cells) and HEVs in tumors and induced the formation of immune cell niches resembling TLS.RO7567132 was well tolerated in both a 2-week non-GLP Maximum tolerated dose/Dose range-finding (MTD/DRF) study and a 4-week GLP toxicology study in cynomolgus monkeys at doses up to 10 mg/kg, with no associated adverse findings.RO7567132 is currently being tested in an open-label, multicenter, dose-escalation, randomized, phase1 study (NCT06537310) to evaluate safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of RO7567132, as a single agent and in combination..."
Clinical • Immunomodulating • IO biomarker • Stroma • Breast Cancer • Colorectal Cancer • Fibrosarcoma • Oncology • Sarcoma • Solid Tumor • CXCL13 • TNFA
September 20, 2024
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
(clinicaltrials.gov)
- P1 | N=180 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor
August 05, 2024
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
(clinicaltrials.gov)
- P1 | N=180 | Not yet recruiting | Sponsor: Hoffmann-La Roche
Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1